Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which completed Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montréal, Canada.

Current Quarter	$-0.19	Next Quarter	$-0.19
Current Year	$-0.73	Next Year	$-0.98
QoQ Growth	+0.0%	YoY Growth	-34.2%
3Y EPS CAGR	+13.1%	Target Price	$3.75
Consensus	Buy	Upside	+55.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MIST	$2.41	-18.31%	28.04M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MIST	$2.41	-18.3%	28.04M
3
4
5
6

MIST

MIST

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Milestone Pharmaceuticals Inc. Data in Excel

Get Milestone Pharmaceuticals Inc. Data in Excel